Trials / Not Yet Recruiting
Not Yet RecruitingNCT06985316
An Exploratory Clinical Study Evaluating the Efficacy and Safety of Tunlametinib Combined With Fruquintinib in the Third-line Treatment of Advanced Colorectal Cancer Patients With RAS Mutations.
- Status
- Not Yet Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 34 (estimated)
- Sponsor
- Liu Huang · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is a prospective, open-label, single-arm clinical study aimed at evaluating the efficacy and safety of Tunlametinib combined with Fruquintinib in the third-line treatment of advanced colorectal cancer patients with RAS mutations.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tunlametinib combined with Fruquintinib | Tunlametinib combined with Fruquintinib |
Timeline
- Start date
- 2025-05-19
- Primary completion
- 2028-04-27
- Completion
- 2028-04-27
- First posted
- 2025-05-22
- Last updated
- 2025-05-22
Source: ClinicalTrials.gov record NCT06985316. Inclusion in this directory is not an endorsement.